Back in the summer of 1980, gastroenterologist Jean-Pierre Raufman started working at the National Institutes of Health
Zepbound (technically a dual GIP/GLP-1 agonist) is FDA-approved specifically to treat obstructive sleep apnea, but GLP-1s have been broadly found to reduce snoring
Its recommended to stay hydrated and engage in light physical activity to help the body eliminate the disrupted fat cells.
Ongoing research and development efforts, including novel formulations, dual- and triple-agonist therapies, and extended-release oral agents, hold promise for enhancing accessibility, tolerability, and sustained benefits
One According to a The 2016 review mentioned earlier reported several other findings: Rodent studies have shown that an olive oil-enriched diet increased GLP-1 secretion, glucose-stimulated insulin secretion, and glucose tolerance